Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 18 of 18 results for afatinib

  1. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development [GID-TA10899] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic

    Diagnostics guidance
    Published
    14 August 2013
    View recommendations

    Sections for DG9

  3. Research recommendations

    clinical trials comparing the effectiveness of the tyrosine kinase inhibitors (afatinib, erlotinib and gefitinib) in EGFR...